110 related articles for article (PubMed ID: 8503403)
1. Treatment of active Crohn's disease with an oral slow-release budesonide formulation.
Roth M; Gross V; Schölmerich J; Ueberschaer B; Ewe K
Am J Gastroenterol; 1993 Jun; 88(6):968-9. PubMed ID: 8503403
[No Abstract] [Full Text] [Related]
2. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.
Gross V; Andus T; Caesar I; Bischoff SC; Lochs H; Tromm A; Schulz HJ; Bär U; Weber A; Gierend M; Ewe K; Schölmerich J
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):905-9. PubMed ID: 8889459
[TBL] [Abstract][Full Text] [Related]
3. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
[TBL] [Abstract][Full Text] [Related]
4. Controlled-release budesonide in Crohn's disease.
Drug Ther Bull; 1997 Apr; 35(4):30-1. PubMed ID: 9282408
[TBL] [Abstract][Full Text] [Related]
5. Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study.
Novacek G; Kleinberger M; Vogelsang H; Moser G; Lochs H
Z Gastroenterol; 1995 May; 33(5):251-4. PubMed ID: 7610692
[TBL] [Abstract][Full Text] [Related]
6. Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Germany Budesonide Study Group.
Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
Z Gastroenterol; 1995 May; 33(5):247-50. PubMed ID: 7610691
[TBL] [Abstract][Full Text] [Related]
7. Oral budesonide in active Crohn's disease.
Löfberg R; Danielsson A; Salde L
Aliment Pharmacol Ther; 1993 Dec; 7(6):611-6. PubMed ID: 8161666
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of controlled-release budesonide in preserving bone mineral density in patients with Crohn's disease.
Abreu MT
Nat Clin Pract Gastroenterol Hepatol; 2005 May; 2(5):210-1. PubMed ID: 16265201
[No Abstract] [Full Text] [Related]
9. [Locally acting glucocorticoids in chronic intestinal inflammation].
Lamers CB; van der Sluys Veer A; Wagtmans MJ; van Hogezand RA
Ned Tijdschr Geneeskd; 1994 Dec; 138(51):2533-5. PubMed ID: 7830800
[No Abstract] [Full Text] [Related]
10. Budesonide modified-release capsules.
Baker DE
Rev Gastroenterol Disord; 2001; 1(3):147-55. PubMed ID: 12120182
[TBL] [Abstract][Full Text] [Related]
11. Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis.
Gross V
Expert Opin Pharmacother; 2008 May; 9(7):1257-65. PubMed ID: 18422482
[TBL] [Abstract][Full Text] [Related]
12. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.
Campieri M; Ferguson A; Doe W; Persson T; Nilsson LG
Gut; 1997 Aug; 41(2):209-14. PubMed ID: 9301500
[TBL] [Abstract][Full Text] [Related]
13. [New therapeutic possibilities in chronic inflammatory bowel diseases].
Zeitz M
Praxis (Bern 1994); 1997 Jun; 86(25-26):1071-4. PubMed ID: 9289806
[TBL] [Abstract][Full Text] [Related]
14. [Budesonide in acute attacks of Crohn disease of medium intensity].
Marteau P
Gastroenterol Clin Biol; 1995 Apr; 19(4):459-60. PubMed ID: 7672543
[No Abstract] [Full Text] [Related]
15. Budesonide in Crohn's disease: findings of a compassionate-use program.
Lyckegaard E; Håkansson K; Bengtsson B
Hepatogastroenterology; 2007; 54(79):2024-7. PubMed ID: 18251152
[TBL] [Abstract][Full Text] [Related]
16. Budesonide in inflammatory bowel disease.
Lamers CB; Wagtmans MJ; van der Sluys Veer A; van Hogezand RA; Griffioen G
Neth J Med; 1996 Feb; 48(2):60-3. PubMed ID: 8819801
[TBL] [Abstract][Full Text] [Related]
17. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group.
Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
Gastroenterology; 1996 Jan; 110(1):45-51. PubMed ID: 8536887
[TBL] [Abstract][Full Text] [Related]
18. The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease.
Rutgeerts P
Mediators Inflamm; 1998; 7(3):137-40. PubMed ID: 9705597
[TBL] [Abstract][Full Text] [Related]
19. Budesonide for inflammatory bowel disease. Is it a magic bullet?
Sachar DB
N Engl J Med; 1994 Sep; 331(13):873-4. PubMed ID: 8078535
[No Abstract] [Full Text] [Related]
20. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
Sandborn WJ; Feagan BG; Lichtenstein GR
Aliment Pharmacol Ther; 2007 Oct; 26(7):987-1003. PubMed ID: 17877506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
